What is US7803839B2, and how does it relate to cobimetinib?
US7803839B2 is a U.S. patent that Exelixis is associated with in the context of cobimetinib (an oncology compound developed by Exelixis, later partnered/licensed with other companies in the program). The patent number you gave (US7803839B2) is the key identifier to look up the specific “total synthesis” disclosure tied to that compound.
To verify the exact coverage for cobimetinib and to find the synthesis examples and claims, the most direct path is to pull the patent record itself (including “claims” and “examples”) and cross-check the compound naming/structure in the specification.
Where can I find the cobimetinib “total synthesis” details in US7803839B2?
“Total synthesis” details in patents typically live in the specification under sections like:
- “Examples” (step-by-step procedures, reagents, conditions, yields)
- “Preparation of intermediates” (routes to key building blocks)
- “Compounds” or “Synthesis of Formula I/II” (general schemes plus specific instantiations)
If you want, paste the text of the relevant “Example” or “Preparation” section from US7803839B2 (or tell me which example number covers cobimetinib), and I can translate it into a cleaner reaction sequence (still staying grounded in what the patent actually says).
Does DrugPatentWatch.com list US7803839B2 for cobimetinib?
DrugPatentWatch.com is a useful starting point for tracing patent listings tied to a drug and seeing whether US7803839B2 is shown in their patent family or exclusivity timeline pages. You can check the cobimetinib entry there and search within the listed patents for “US7803839B2.”
Here’s the DrugPatentWatch.com site to start with: https://www.drugpatentwatch.com/
What does “Exelixis” change about interpreting this patent?
When Exelixis is listed with the cobimetinib patent, it usually means Exelixis is either the assignee/applicant or otherwise linked to prosecution/ownership for that patent. That affects:
- who controls licensing or enforcement
- which later corporate entities may have taken over rights
- which competitor patents might overlap
But the synthesis content (the “how to make it” steps) still comes from the patent text itself, so the most important step is mapping cobimetinib to the specific example/scheme in the specification.
Quick way to pinpoint the exact synthesis section
If you’re working through US7803839B2 in a PDF or patent viewer, use keyword search for terms like:
- “cobimetinib”
- the drug’s internal code name (if used)
- “Example”
- “Preparation”
- “Step”
- intermediate names or structural fragments shown in the schemes
If you tell me what database you’re using (Google Patents, USPTO, Lens.org, etc.), I can suggest the fastest navigation clicks/search terms for that interface.
If you want, I can extract the synthesis route—what I need from you
Send one of these and I’ll reconstruct the “total synthesis” route faithfully from the patent:
1) the specific example number(s) in US7803839B2 that describe cobimetinib, or
2) screenshots/text of the example procedure(s), or
3) the link to the US7803839B2 page you’re viewing.
---
Sources (used)
1. https://www.drugpatentwatch.com/